212 related articles for article (PubMed ID: 31542851)
21. Biosimilar filgrastim (leucostim®) have similar efficacy in steady-state hematopoietic progenitor cell mobilization compared to original filgrastim (neupogen®) and lenograstim (granocyte®): A retrospective multicenter study.
Kayıkçı Ö; Tekgündüz E; Kaya AH; Göker H; Aslan A; İskender D; Namdaroglu S; Tetik A; Koçubaba Ş; Altuntaş F
Transfus Apher Sci; 2017 Dec; 56(6):832-835. PubMed ID: 29162397
[TBL] [Abstract][Full Text] [Related]
22. Biosimilar granulocyte colony-stimulating factor is effective in reducing the duration of neutropenia after autologous peripheral blood stem cell transplantation.
Cioch M; Jawniak D; Kotwica K; Wach M; Mańko J; Gorący A; Klimek P; Mazurkiewicz E; Jarosz P; Hus M
Transplant Proc; 2014 Oct; 46(8):2882-4. PubMed ID: 25380941
[TBL] [Abstract][Full Text] [Related]
23. Mobilization of PBSC for allogeneic transplantation by the use of the G-CSF biosimilar XM02 in healthy donors.
Schmitt M; Xu X; Hilgendorf I; Schneider C; Borchert K; Gläser D; Freund M; Schmitt A
Bone Marrow Transplant; 2013 Jul; 48(7):922-5. PubMed ID: 23318540
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim.
Marchesi F; Terrenato I; Papa E; Tomassi M; Falcucci P; Gumenyuk S; Palombi F; Pisani F; Renzi D; Romano A; Spadea A; Regazzo G; Rizzo MG; De Rienzo M; Ripellino C; Sgromo S; Viggiani C; Ponte E; Kayal R; Cordone I; Foddai ML; Mengarelli A
Ann Hematol; 2024 Mar; 103(3):947-956. PubMed ID: 38189833
[TBL] [Abstract][Full Text] [Related]
25. Is split-dose better than single-dose? Results of Turkish Stem Cell Coordination Center (TURKOK) donors in the era of rising biosimilar G-CSF.
Pınar İE; Özkocaman V; Özkalemkaş F; Durgut H; Dakiki B; Ersal T; Gürsoy V; Yalçın C; Orhan B; Candar Ö; Ali R
J Clin Apher; 2022 Oct; 37(5):430-437. PubMed ID: 35689647
[TBL] [Abstract][Full Text] [Related]
26. Biosimilar Filgrastim in Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization and Post-Transplant Hematologic Recovery.
Marchesi F; Mengarelli A
Curr Med Chem; 2016; 23(21):2217-29. PubMed ID: 27183986
[TBL] [Abstract][Full Text] [Related]
27. Long-Term Safety of Short-Term Administration of Filgrastim (rhG-CSF) and Leukophresis Procedure in Healthy Children: Application of Peripheral Blood Stem Cell Collection in Pediatric Donors.
Behfar M; Faghihi-Kashani S; Hosseini AS; Ghavamzadeh A; Hamidieh AA
Biol Blood Marrow Transplant; 2018 Apr; 24(4):866-870. PubMed ID: 29284143
[TBL] [Abstract][Full Text] [Related]
28. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation.
Kröger N; Renges H; Krüger W; Gutensohn K; Löliger C; Carrero I; Cortes L; Zander AR
Br J Haematol; 2000 Dec; 111(3):761-5. PubMed ID: 11122135
[TBL] [Abstract][Full Text] [Related]
29. Race and ethnicity influences collection of granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells from unrelated donors, a Center for International Blood and Marrow Transplant Research analysis.
Hsu JW; Wingard JR; Logan BR; Chitphakdithai P; Akpek G; Anderlini P; Artz AS; Bredeson C; Goldstein S; Hale G; Hematti P; Joshi S; Kamble RT; Lazarus HM; O'Donnell PV; Pulsipher MA; Savani BN; Schears RM; Shaw BE; Confer DL
Biol Blood Marrow Transplant; 2015 Jan; 21(1):165-71. PubMed ID: 25316111
[TBL] [Abstract][Full Text] [Related]
30. Mobilization of hematopoietic progenitor cells from allogeneic healthy donors using a new biosimilar G-CSF (Zarzio®).
Antelo ML; Zabalza A; Sánchez Antón MP; Zalba S; Aznar M; Mansilla C; Ramírez N; Olavarría E
J Clin Apher; 2016 Feb; 31(1):48-52. PubMed ID: 26011178
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of a biosimilar granulocyte colony-stimulating factor (filgrastim XM02) for peripheral blood stem cell mobilization and transplantation: a single center experience in Japan.
Yoshimura H; Hotta M; Nakanishi T; Fujita S; Nakaya A; Satake A; Ito T; Ishii K; Nomura S
J Blood Med; 2017; 8():5-12. PubMed ID: 28182150
[TBL] [Abstract][Full Text] [Related]
32. Use of a biosimilar granulocyte colony-stimulating factor for peripheral blood stem cell mobilization: an analysis of mobilization and engraftment.
Publicover A; Richardson DS; Davies A; Hill KS; Hurlock C; Hutchins D; Jenner MW; Johnson PW; Lamb J; Launders H; McKeag N; Newman J; Orchard KH
Br J Haematol; 2013 Jul; 162(1):107-11. PubMed ID: 23614650
[TBL] [Abstract][Full Text] [Related]
33. Current use of biosimilar G-CSF for haematopoietic stem cell mobilisation.
Pahnke S; Egeland T; Halter J; Hägglund H; Shaw BE; Woolfrey AE; Szer J;
Bone Marrow Transplant; 2019 Jun; 54(6):858-866. PubMed ID: 30283148
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of three filgrastim-intended copies for hematopoietic stem cell mobilization in healthy adult and pediatric donors in Mexico.
Gómez-De León A; Bugarin-Estrada E; Colunga-Pedraza PR; Colunga-Pedraza JE; Salazar-Riojas R; Valdés-Galván M; López-García YK; López-Garza M; Gutiérrez-Aguirre CH; Cantú-Rodríguez OG; Mancías-Guerra C; González-Llano O; Gómez-Almaguer D
J Clin Apher; 2019 Oct; 34(5):537-544. PubMed ID: 30946494
[TBL] [Abstract][Full Text] [Related]
35. Potential cost savings from chemotherapy-induced febrile neutropenia with biosimilar filgrastim and expanded access to targeted antineoplastic treatment across the European Union G5 countries: a simulation study.
Sun D; Andayani TM; Altyar A; MacDonald K; Abraham I
Clin Ther; 2015 Apr; 37(4):842-57. PubMed ID: 25704107
[TBL] [Abstract][Full Text] [Related]
36. Comparison of biosimilar filgrastim with originator filgrastim for peripheral blood stem cell mobilization and engraftment in patients with multiple myeloma undergoing autologous stem cell transplantation.
Pham T; Patil S; Fleming S; Avery S; Walker P; Wei A; Curtis D; Stuart G; Klarica D; O'Brien M; Morris K; Das T; Bollard G; Muirhead J; Coutsouvelis J; Spencer A
Transfusion; 2015 Nov; 55(11):2709-13. PubMed ID: 26173921
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of granulocyte colony-stimulating factor biosimilars in engraftment after autologous stem cell transplantation for haematological malignancies: a 4-year, single institute experience with different conditioning regimens.
Bassi S; Stroppa EM; Moroni CF; Arbasi MC; Trabacchi E; Di Franco A; Lazzaro A; Bernuzzi P; Moretto M; Arcari A; Bosi C; Riva A; Cavanna L; Vallisa D
Blood Transfus; 2015 Jul; 13(3):478-83. PubMed ID: 25761321
[TBL] [Abstract][Full Text] [Related]
38. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
39. Mexican Biosimilar Filgrastim for Autologous Hematopoietic Stem Cell Mobilization and Transplantation.
León-González M; León-Peña AA; Vallejo-VIllalobos MF; Núñez-Cortés AK; Ruiz-Argüelles A; Ruiz-Argüelles GJ
Rev Invest Clin; 2016; 68(4):181-3. PubMed ID: 27623036
[TBL] [Abstract][Full Text] [Related]
40. [Randomized clinical study for two types of recombinant human granulocyte colony-stimulating factor mobilizing peripheral blood and bone marrow stem cells in patients receiving allogeneic hematopoietic stem cell transplantation].
Zhang XH; Huang XJ; Liu DH; Liu KY; Han W; Chen H; Wang FR; Chen YH; Wang JZ; Zhao T; Wang Y; Xu LP
Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(30):2116-9. PubMed ID: 20058615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
